Jim Hoffman: Why NET-Removing Blood Purification Should Be a First Resort, Not a Last
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, posted on LinkedIn:
“We should be investigating blood purification therapies that can help sick patients remove extracellular chromatin from the blood early on in response to all infections, since these therapies may help reduce illness severity, shorten recovery time, potentially reduce the need for toxic levels of antimicrobials and very likely could help prevent the development of more severe, life-threatening, sepsis-like illnesses, reducing the risk for hospitalization and ICU treatment. Instead, we could prognostically track this chromatin in the blood and potentially set up local wellness clinics capable of performing safe apheresis procedures to help sick patients remove it.
It is largely our dysregulated innate immune response to infection that matters most, and part of this damaging response is the direct result of persistent NETosis dysregulation, which needs more specific targeted therapy. Why not try extracorporeal blood purification treatments known to deplete extracellular chromatin, which have largely been used as a last resort treatment, known as “compassionate use”, earlier on in the course of post-infection illness, potentially minimizing NETosis-mediated injury?
Likewise, based on the observations of Hetland et al and a separate previous study by Holme et al, a similar persistent rise in extracellular chromatin, positively correlated with life-threatening complications in response to AVV vaccination, which most likely directly worsens blood hemostatic control. If true, why not try removing this elevated extracellular chromatin from the blood and see if it can help avert serious life-threatening VITT in response to vaccination gone wrong?
Title: Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects
Authors: Geir Hetland, Magne Kristoffer Fagerhol, Markus Karl Hermann Wiedmann, Arne Vasli Lund Søraas, Mohammad Reza Mirlashari, Lise Sofie Haug Nissen-Meyer, Mette Stausland Istre, Pål Andre Holme, Nina Haagenrud Schultz
Hetland et al 2022
Read full paper here.
“Importantly, using hospital setting (outpatient, inpatient or ICU) as a proxy for disease severity, nucleosome levels increased with disease severity and may serve as a guiding biomarker for treatment” Holdenrieder et al
Title: Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression
Authors: Etienne Cavalier, Julien Guiot, Katharina Lechner, Alexander Dutsch, Mark Eccleston, Marielle Herzog, Thomas Bygott, Adrian Schomburg, Theresa Kelly, Stefan Holdenrieder
Holdenrieder et al 2021
Read full article here.
For more NETosis research in response to infections and vaccination, visit here.
Title: Neutrophil Extracellular Traps Go Viral
Authors: Günther Schönrich, Martin J Raftery
Reviewed by Schonrich and Raftery 16.00366/full 2016 “Supporting this idea, viral infections are associated with transient autoantibody production and are known to mimic SLE, induce SLE onset, or trigger lupus flares (88–90)”.
NET removal, a therapy known reduce the severity of lupus, what about comorbid infections? ‘Supporting this idea, viral infections are associated with transient autoantibody production and are known to mimic SLE, induce SLE onset, or trigger lupus flares (88–90)’.”
Quoting C.W. H.:
“COVID: It’s been a while, but the word triple-demic is making a comeback.
That’s because of a surge of three viruses happening right now: Flu, COVID and RSV cases are up by double digits in New York.
Flu is up 30%, RSV is up 35% and COVID cases are up 15% in New York State according to the most recent data from the state Department of Health.”
Get the lateste with Hemostasis Today.
-
Sep 30, 2026, 15:58Bernhard Merget: New Frontiers in Thrombosis and Stroke Research
-
Sep 30, 2026, 15:39Ifeanyichukwu Ifechidere: The Molecular Orchestra of Primary Hemostasis
-
Sep 30, 2026, 15:28Reassessing the Benefit–Risk Balance of Extended Anticoagulation in Cancer Patients – ESC Working Group on Cardiovascular Pharmacotherapy
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?